Whole-body PET/CT scan during immunotherapy for melanoma
Part of Cancer, Skin clinical trials.
This trial studies how a whole-body PET/CT scan (using a radioactive sugar called FDG) can better track metastatic melanoma in people receiving immune therapy. It may help doctors understand tumor response to medications like nivolumab or pembrolizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have melanoma that has spread to other parts of the body (metastatic melanoma)
- You are currently being treated with an anti–PD-1 medicine (nivolumab or pembrolizumab) or a combination of ipilimumab plus nivolumab
- You can agree to take part in the scan (you do not refuse participation)
- Your doctor says you are eligible to safely have the PET/CT exam
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks an “interim” whole-body scan (PET-CT) partway through treatment to see how well anti-PD-1 immunotherapy (nivolumab or pembrolizumab) is working for advanced melanoma. It may help doctors better understand early treatment response and guide next steps.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial tests a special PET scan that tracks immune activity to see if it can help monitor how well immunotherapy is working in people with various cancers. It is for patients about to start immunotherapy for the first time.
This trial uses a special PET/CT scan (called 18F-grazy-02) to look at a protein in your body that may show how well your immune system is fighting the cancer. It is for people with non-small cell lung cancer or melanoma to help their doctors monitor the effects of immunotherapy.
This trial uses a special PET scan to track how well your tumor responds to immunotherapy. It may help doctors see early on if the treatment is working for you.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.